Hyperkalemia is a common finding in dialysis patients. This is not surprising considering that these patients, with essentially no renal function, have a daily potassium intake of 40-80 m moles. As this amounts to 80-320 m moles over the two to four day interdialytic period, one would almost expect hyperkalemia to be a more severe and universal problem in these patients.
Patients with persistent hyperkalemia are invariably assumed not to be adhering to their diet, and are often warned of the hazards of dietary indiscretion, usually without success. Many of these patients undoubtedly take in too much potassium-rich food. They characteristically present with hyperkalemia as well as high serum urea and phosphate concentrations and excess weight gain.
We suspect, however, that hyperkalemia is not always due to dietary indiscretions. We all know patients prone to hyperkalemia who are conscientious and whose diet is no different from the patients who are not hyperkalemic. Their serum urea and phosphate are not too high and their volume gain is not excessive, suggesting that they have a regulatory problem confined to potassium.
The anephric individual has important regulatory mechanisms that tend to maintain a normal extracellular potassium concentration. A possible failure of one or more of these regulatory mechanisms needs to be considered in patients with isolated hyperkalemia.
The potassium content of a large meal alone would be sufficient to raise the extracellular potassium to near lethal levels, were it not for the remarkable ability of the tissues -mainly skeletal muscle and liverto soak up the potassium as soon as it is absorbed from the gut. Later, in the normal individual, the potassium thus stored is gradually released from the cells and excreted by the kidneys.
In the dialysis patient, where renal excretion is absent or minimal, potassium balance is maintained mainly by dialysis and to some extent by enhanced colonic excretion. To avoid dangerous hyperkalemia the patient is critically dependent on his tissues stor-The International Journal Of Artificial Organs / Vol. 10 / no. 1, 1987/ pp. 17-19 ing the potassium between dialyses. He generally copes with the loss of renal potassium excretory function by increasing aldosterone secretion (1). This facilitates both shifting of potassium into the cells (2) and excreting it through the colon (3) . Sometimes this response may fail, however. Some patientsparticularly those with diabetic nephropathy -have the syndrome of isolated hypoaldosteronism (4) . When they reach the stage of dialysis they probably still have the defect and may thus comprise a subset of dialysis patients particularly prone to hyperkalemia. The extrarenal action of aldosterone is due -at least in part -to stimulation of Na, K-ATPase (5). This enzyme, the biochemical expression of the Na, Kpump, is the major mechanism responsible for transporting potassium into the cells against the membrane electrochemical gradient, and is also involved in potassium excretion by the kidney and colon.
On the other hand, uremia itself inhibits Na, K-AT-Pase in a variety of tissues such as the brain (6), red cells (7) and colon (8). This effect opposes the direct stimulatory action of aldosterone on ATPase, and probably reduces the effectiveness of potassium adaptation.
Other mechanisms that protect against post-prandial hyperkalemia are epinephrine release (9) -a normal response to feeding -and insulin release (10) . Both responses promote potassium entry into the cells and both may be blunted in uremia, in the diabetic as well as in the non-diabetic patient. In uremia the peripheral action of insulin (on skeletal muscle) is often markedly impaired (11) , reducing the ability of the skeletal muscle to store potassium.
Serum levels of noreprinephrine and dopamine are increased in end-stage renal disease (12) . Although the mechanism and significance of this finding is unclear, it is unlikely to represent a higher level of adrenergic stimulation. In fact, many patients with endstage renal disease exhibit autonomic dysfunction. It is thus possible that this protective mechanism against post-prandial hyperkalemia may also be impaired.
In the diabetic dialysis patient the tendency to hyperkalemia is aggravated by hyperglycemia, which favors the release of potassium from the cells, probably due to hyperosmolality (13) . Whereas hyperglycemia induced hyperkalemia is mostly undetected in the normal subject, it may cause hyperkalemia in renal failure. Lethal hyperkalemia in severely hyperglycemic e by Wichlig Editore. 1987 0391-3988/017-08 $02.00/0
Hyperkalemia in dialysis patients with renal failure has indeed been described (14) .
Hyperkalemia may also be worsened by the drugs prescribed to dialysis patients. Toxic blood digitalis concentrations may inhibit the Na, K-pump sufficiently to permit the net potassium exit from the tissues. Digitalis may also blunt the aldosterone response to hyperkalemia. With normal renal function this is usually not a problem because the potassium is readily excreted by the kidneys. In uremia, however, the same digitalis concentrations have resulted in dangerous hyperkalemia unrelated to dietary indiscretions (15) . Thus the patient with renal failure is not only at risk of developing digitalis toxicity, but also at a higher risk of hyperkalemia should toxicity occur.
Beta-adrenergic blocking agents, commonly used as antihypertensive agents, may cause hyperkalemia by interfering with the adrenergic action that facilitates potassium entry into the cells (9). Since this effect is mediated by beta-2 receptors, the non-selective beta-blocking agents are more likely to cause this untoward effect.
Heparin has also been reported to cause hypekalemia (16) , perhaps because it may inhibit aldosterone secretion (17) . Heparin is believed to inhibit the 18hydroxylase step during the synthesis of aldosterone (18) . We are not aware, however. of heparin causing hyperkalemia in the doses and timing employed in hemodialysis.
The converting enzyme inhibitors captopril and enalapril, often prescribed as antihypertensive agents, also favor the development of hyperkalemia (19) . Inhibition of the converting enzyme inhibits the formation of angiotensin II, a major stimulatory factor of aldosterone secretion. Hyperkalemia may thus develop whenever the angiotensin-aldosterone system is blunted, particularly in an individual whose eukalemic state is so highly dependent on aldosterone, such as in uremia.
In conclusion, there are many possible causes of hyperkalemia in dialysis patients. All too frequently the physicians and dieticians assume that a persistent elevation of serum potassium is due to non-compliance. Every effort should be made to identify other possible correctable causes and take appropriate measures, thus adding to the quality of life of the patient on dialysis. 
